{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:29:37Z","timestamp":1768537777746,"version":"3.49.0"},"reference-count":30,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"4","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["biomedica"],"abstract":"<jats:p>Introduction: Multidrug-resistant tuberculosis treatment is effective in 50% of patients due to several factors including antibiotic susceptibility of the microorganism, adverse treatment reactions, social factors, and associated comorbidities.Objectives: In this study, we describe the demographics, clinical characteristics, and factors associated with treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) patients in Medell\u00edn, Colombia.Materials and methods: We conducted a retrospective analysis using data from patients diagnosed with MDR-TB attending Hospital La Mar\u00eda in Medell\u00edn, Colombia, for treatment between 2010 and 2015. Patients were categorized as having successful (cured) or poor (failure, lost to follow-up, and death) treatment outcomes. Associations between demographic, clinical factors, laboratory results, treatment outcomes, and follow-up information were evaluated by univariate, multivariate, and multiple correspondence analyses.Results: Of the 128 patients with MDR-TB, 77 (60%) had successful outcomes. Of those with poor outcomes, 26 were lost to follow-up, 15 died, and 10 were treatment failures. Irregular treatment, the presence of comorbidities, and positive cultures after more than two months of treatment were associated with poor outcomes compared to successful ones (p&lt;0.05 for all). The multiple correspondence analyses grouped patients who were lost to follow-up, had HIV, and drug addiction, as well as patients with treatment failure, irregular treatment, and chronic obstructive pulmonary disease.Conclusion: The recognition of factors affecting treatment is essential and was associated with treatment outcomes in this series of patients. Early identification of these factors should increase the rates of treatment success and contribute to MDR-TB control.<\/jats:p>","DOI":"10.7705\/biomedica.5072","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T21:00:38Z","timestamp":1607029238000},"page":"616-625","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis."],"prefix":"10.7705","volume":"40","author":[{"given":"\u00c1ngela","family":"Tob\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego H.","family":"C\u00e1ceres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria I.","family":"Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa M.","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Fadul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizeth","family":"Paniagua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"101666","unstructured":"World Health Organization. Global tuberculosis report \u2013 2012. Accessed on: December 5, 2018. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/75938"},{"key":"101667","unstructured":"World Health Organization. Global tuberculosis report \u2013 2017. Accessed on: November 8, 2018. Available at: https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2017_main_text.pdf"},{"key":"101668","unstructured":"Luc\u00eda M, Mart\u00ednez O, Enrique M, Dur\u00e1n M, Pacheco-Garc\u00eda OE, Bonilla HQ, et al. Protocolo de vigilancia en salud publica tuberculosis \u2013 2016. Accessed on: November 12, 2018. Available at: http:\/\/www.saludpereira.gov.co\/medios\/Tuberculosis_PROTOCOLO_farmacoresistente2016.pdf"},{"key":"101669","unstructured":"Secretar\u00eda de Salud y Protecci\u00f3n Social de Antioquia. Situaci\u00f3n de la tuberculosis en el departamento de Antioquia 2015-2016. Bolet\u00edn Informaci\u00f3n para la Acci\u00f3n - 2017. Accessed on: October 5, 2018. Available at: https:\/\/www.dssa.gov.co\/images\/Bia_%20Tuberculosis_Mayo2017.pdf"},{"key":"101670","doi-asserted-by":"crossref","unstructured":"Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lee JW, et al. Increasing transparency in partnerships for health--introducing the Green Light Committee. Trop Med Int Health. 2002;7:970-6. https:\/\/doi.org\/10.1046\/j.1365-3156.2002.00960.x","DOI":"10.1046\/j.1365-3156.2002.00960.x"},{"key":"101671","unstructured":"World Health Organization. Definitions and reporting framework for tuberculosis 2013 revision \u20132014. Accessed on: July 11, 2018. Available at: https:\/\/www.who.int\/tb\/publications\/definitions\/en\/"},{"key":"101672","doi-asserted-by":"crossref","unstructured":"Pfyffer GE, Palicova F. Mycobacterium: General characteristics, laboratory detection, and staining procedures. Manual of clinical microbiology, 10th edition. Washington, D.C.: American Society of Microbiology; 2011. p. 472-502.","DOI":"10.1128\/9781555816728.ch28"},{"key":"101673","unstructured":"Robledo J, Mej\u00eda GI, Paniagua L, Mart\u00edn A, Guzm\u00e1n A. Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method. Int J Tuberc Lung Dis. 2008;12:1482-4."},{"key":"101674","unstructured":"Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis. 2008;12:1449-55."},{"key":"101675","unstructured":"Clinical and Laboratory Standards Institute. M24-A2 Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes. 2nd edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2011."},{"key":"101676","doi-asserted-by":"crossref","unstructured":"Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol. 2006;44:688\u201392. https:\/\/doi.org\/10.1128\/JCM.44.3.688-692.2006","DOI":"10.1128\/JCM.44.3.688-692.2006"},{"key":"101677","unstructured":"Instituto Nacional de Salud. Lineamientos para el manejo program\u00e1tico de los pacientes con tuberculosis farmacorresistente \u2013 2013. Accessed on: July 15, 2018. Available at: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VS\/PP\/ET\/lineamientos-tbfarmacorresistente.pdf"},{"key":"101678","doi-asserted-by":"crossref","unstructured":"Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrugresistant tuberculosis: A systematic review and meta-analysis. PLoS One. 2009;4:e6914. https:\/\/doi.org\/10.1371\/journal.pone.0006914","DOI":"10.1371\/journal.pone.0006914"},{"key":"101679","doi-asserted-by":"crossref","unstructured":"Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar J-WC. Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. Int J Mycobacteriol. 2016;5:S44-5. https:\/\/doi.org\/10.1016\/j.ijmyco.2016.07.003","DOI":"10.1016\/j.ijmyco.2016.07.003"},{"key":"101680","doi-asserted-by":"crossref","unstructured":"Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: Systematic review. Trop Med Int Health. 2010;15:1-15. https:\/\/doi.org\/10.1111\/j.1365-3156.2010.02508.x","DOI":"10.1111\/j.1365-3156.2010.02508.x"},{"key":"101681","doi-asserted-by":"crossref","unstructured":"Kuchukhidze G, Kumar AM, de Colombani P, Khogali M, Nanava U, Blumberg HM, et al. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action. 2014;4:S41-6. https:\/\/doi.org\/10.5588\/pha.14.0048","DOI":"10.5588\/pha.14.0048"},{"key":"101682","doi-asserted-by":"crossref","unstructured":"Surya PI, Davies FL, Bruchfeld J, Hak E, Alffenaar J-W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018;77:469-78. https:\/\/doi.org\/10.1016\/j.jinf.2018.10.004","DOI":"10.1016\/j.jinf.2018.10.004"},{"key":"101683","doi-asserted-by":"crossref","unstructured":"Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: A retrospective cohort study. Lancet. 2010;375:1798-807. https:\/\/doi.org\/10.1016\/S0140-6736(10)60492-8","DOI":"10.1016\/S0140-6736(10)60492-8"},{"key":"101684","doi-asserted-by":"crossref","unstructured":"Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: Retrospective multi-center investigation. PLoS One. 2013;8:e82943. https:\/\/doi.org\/10.1371\/journal.pone.0082943","DOI":"10.1371\/journal.pone.0082943"},{"key":"101685","unstructured":"Caminero JA. Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int J Tuberc Lung Dis. 2006;10:829-37."},{"key":"101686","doi-asserted-by":"crossref","unstructured":"Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17:6-16.","DOI":"10.5588\/ijtld.12.0198"},{"key":"101687","doi-asserted-by":"crossref","unstructured":"Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug-resistant tuberculosis. J Pharmacol Pharmacother. 2014;5:145-9. https:\/\/doi.org\/10.4103\/0976-500X.130062","DOI":"10.4103\/0976-500X.130062"},{"key":"101688","doi-asserted-by":"crossref","unstructured":"Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: A secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3:201-9. https:\/\/doi.org\/10.1016\/S2213-2600(15)00036-3","DOI":"10.1016\/S2213-2600(15)00036-3"},{"key":"101689","unstructured":"World Health Organization. The shorter MDR-TB regimen \u2013 2016. Accessed on: December 3, 2018. Available at: https:\/\/www.who.int\/tb\/Short_MDR_regimen_factsheet.pdf"},{"key":"101690","doi-asserted-by":"crossref","unstructured":"Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;15:871-85. https:\/\/doi.org\/10.5588\/ijtld.10.0352","DOI":"10.5588\/ijtld.10.0352"},{"key":"101691","doi-asserted-by":"crossref","unstructured":"Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, et al. A global perspective on pyrazinamide resistance: Systematic review and meta-analysis. PLoS One. 2015;10:e0133869. https:\/\/doi.org\/10.1371\/journal.pone.0133869","DOI":"10.1371\/journal.pone.0133869"},{"key":"101692","unstructured":"Ghafoor T, Ikram A, Abbasi SA, Zaman G, Ayyub M, Palomino JC, et al. Sensitivity pattern of second line anti-tuberculosis drugs against clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Coll Physicians Surg Pak. 2015;25:250-3."},{"key":"101693","doi-asserted-by":"crossref","unstructured":"Simpson G, Coulter C, Weston J, Knight T, Carter R, Vincent S, et al. Resistance patterns of multidrug-resistant tuberculosis in Western Province, Papua New Guinea. Int J Tuberc Lung Dis. 2011;15:551\u20132. https:\/\/doi.org\/10.5588\/ijtld.10.0347","DOI":"10.5588\/ijtld.10.0347"},{"key":"101694","doi-asserted-by":"crossref","unstructured":"Rueda J, Realpe T, Mej\u00eda GI, Zapata E, Rozo JC, Ferro BE, et al. Genotypic analysis of genes associated with independent resistance and cross-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59:7805-10. https:\/\/doi.org\/10.1128\/AAC.01028-15","DOI":"10.1128\/AAC.01028-15"},{"key":"101695","doi-asserted-by":"crossref","unstructured":"Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: A cohort study. Lancet. 2014;383:1230-9. https:\/\/doi.org\/10.1016\/S0140-6736(13)62675-6","DOI":"10.1016\/S0140-6736(13)62675-6"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/5072\/4563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/5072\/4563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T20:35:03Z","timestamp":1607114103000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/5072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.5072","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,2]]},"assertion":[{"value":"2020-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Original articles","name":"content_type","label":"Content Type"}]}}